10-Q: ASHS Q3 2025: Direct Patient Services Drive Revenue Growth

American Shared Hospital Services reports increased Q3 2025 revenue driven by direct patient services, despite a significant drop in cash and working capital.

Summary

• Total revenues increased by $172,000 to $7,171,000 for the three months ended September 30, 2025, and by $1,083,000 to $20,354,000 for the nine months ended September 30, 2025, compared to the prior year periods.
• Direct patient services revenue grew significantly, increasing by $347,000 to $4,034,000 in Q3 2025 and by $2,848,000 to $10,655,000 year-to-date, primarily due to the RI Acquisition and the Puebla, Mexico facility.
• Leasing segment revenue decreased by $175,000 to $3,137,000 in Q3 2025 and by $1,765,000 to $9,699,000 year-to-date, mainly due to lower PBRT volumes and expired Gamma Knife contracts.
• Net loss attributable to American Shared Hospital Services improved in Q3 2025 to $(17,000) from $(207,000) in Q3 2024, but worsened year-to-date to $(922,000) from a net income of $3,514,000 in the prior year, largely due to the absence of the bargain purchase gain from the RI Acquisition.
• Cash and cash equivalents decreased by $5,930,000 to $5,095,000 at September 30, 2025, from $11,025,000 at December 31, 2024.
• Working capital significantly decreased to $3,420,000 at September 30, 2025, from $15,853,000 at December 31, 2024.
• The company failed to comply with a maximum funded debt to EBITDA ratio covenant as of June 30, 2025, but received a limited waiver from Fifth Third Bank on September 30, 2025.

Sentiment

Score: 3

Explanation: While Q3 showed some improvement in net loss, the year-to-date performance is significantly worse than the prior year (excluding the one-time gain). The substantial decrease in cash and working capital, coupled with a debt covenant waiver and upcoming debt maturity, indicates significant financial pressure and uncertainty regarding future financing, despite revenue growth in direct patient services.

Positives

• Overall revenues increased for both the three-month ($172,000 increase) and nine-month ($1,083,000 increase) periods ended September 30, 2025.
• Direct patient services revenue showed strong growth, increasing by $347,000 in Q3 2025 and $2,848,000 year-to-date, driven by new facilities in Rhode Island and Puebla, Mexico.
• Net loss attributable to American Shared Hospital Services significantly narrowed in Q3 2025 to $(17,000) from $(207,000) in Q3 2024.
• Net cash provided by operating activities improved substantially to $3,802,000 for the nine months ended September 30, 2025, compared to a net cash used of $(107,000) in the prior year.
• Received a limited waiver from Fifth Third Bank for non-compliance with a debt covenant as of June 30, 2025, maintaining compliance as of September 30, 2025.
• The One Big Beautiful Bill Act (OBBBA) is expected to decrease U.S. cash taxes in 2025.

Negatives

• Cash and cash equivalents decreased significantly by $5,930,000 to $5,095,000 at September 30, 2025, from $11,025,000 at December 31, 2024.
• Working capital decreased substantially by $12,433,000 to $3,420,000 at September 30, 2025, from $15,853,000 at December 31, 2024.
• Leasing segment revenue decreased by $175,000 in Q3 2025 and $1,765,000 year-to-date, primarily due to lower PBRT volumes and the expiration of three Gamma Knife customer contracts.
• Year-to-date net loss attributable to American Shared Hospital Services increased to $(922,000) in 2025, a significant decline from net income of $3,514,000 in 2024, largely due to the absence of the prior year's bargain purchase gain.
• Operating loss for the nine-month period ended September 30, 2025, increased to $(2,187,000) from $(975,000) in the prior year.
• The company's disclosure controls and procedures were not effective as of September 30, 2025, due to a material weakness in internal controls over financial reporting (insufficient personnel and resources).
• The Credit Agreement with Fifth Third Bank matures in April 2026, and while the company is optimistic about an extension, there is no assurance, which could adversely impact liquidity.

Risks

• Failure to comply with debt covenants could lead to termination of credit commitments and immediate repayment of outstanding borrowings.
• The Credit Agreement with Fifth Third Bank matures in April 2026, and inability to negotiate an extension would adversely impact liquidity and ability to meet commitments.
• The company has commitments to purchase and install two Leksell Gamma Knife Esprit Systems and two Linear Accelerator (LINAC) systems totaling $7,884,000, and there is no assurance that financing will be available on acceptable terms.
• The company's disclosure controls and procedures were not effective due to a material weakness in internal controls over financial reporting, which could adversely affect the ability to record, process, summarize, and report financial information.
• The small and relatively illiquid market for the company's stock.
• Dependence on reimbursement rates (e.g., CMS rates for Medicare Gamma Knife and PBRT treatments).
• Competition and alternatives to the company's services.
• Technological advances and the risk of equipment obsolescence.
• Significant investment in the proton beam radiation therapy business.
• Breaches in security of information technology.
• International operations (Peru, Ecuador) can be impacted by local legislation changes or social and economic factors affecting patient volumes.

Future Outlook

The company anticipates installing two Leksell Gamma Knife Esprit Systems and one Linear Accelerator (LINAC) in Q1 or Q2 2026 or later at existing customer sites, with another LINAC reserved for a future site. It intends to finance these commitments but cannot assure financing availability on acceptable terms. The Newco facility in Guadalajara, Mexico, is not expected to begin treating patients until Q2 2026. The One Big Beautiful Bill Act (OBBBA) is expected to decrease U.S. cash taxes in 2025 without materially impacting the effective tax rate.

Management Comments

• The results of operations for the three and nine-month periods ended September 30, 2025 are not necessarily indicative of results on an annualized basis.
• The Company believes that its cash on hand, cash flow from operations, and other cash resources are adequate to meet its scheduled debt obligations and working capital requirements during the next 12 months.
• The Company is optimistic it will be able to negotiate an extension to the Credit Agreement, if the Company is unable to do so, the Company's liquidity will be adversely impacted and the Company's ability to satisfy all of its commitments over the next twelve months in accordance with their current terms would be jeopardized.
• The Company expects this change [internalizing Rhode Island revenue cycle] to provide more control and efficiency to this process overall.
• The Company will continue to assess the need for additional resources, especially in the finance and accounting areas, as the Company's business continues to grow and expand.

Industry Context

The company operates in the specialized medical equipment leasing and direct patient services sector for radiosurgery and advanced radiation therapy. The shift towards direct patient services, particularly through acquisitions like the RI Companies and new facilities in Mexico, aligns with a strategy to diversify revenue streams beyond traditional equipment leasing, which has seen declining volumes in some areas (PBRT, some Gamma Knife contracts). The reliance on government payors in international markets (Peru, Ecuador) highlights exposure to local legislative and socio-economic factors, a common challenge for healthcare providers with global operations. The ongoing need for capital expenditures for equipment upgrades (Esprit, LINAC) reflects the high-tech and capital-intensive nature of the industry.

Management Changes

Corporate Governance

Related Party Transactions

• Equipment purchases and de-install costs from Elekta (19% owner of GKF subsidiary) totaled $1,243,000 for Q3 2025 and $4,412,000 for YTD 2025.
• Costs incurred to maintain equipment from Elekta totaled $278,000 for Q3 2025 and $729,000 for YTD 2025.
• Commitments to purchase and install two Esprit units, two LINACs, and service related equipment from Elekta totaled $11,045,000 as of September 30, 2025.
• Related party liabilities (accounts payable, asset retirement obligation, and other accrued liabilities) were $1,471,000 as of September 30, 2025.

Stakeholder Impact

• Shareholders: Experience a year-to-date net loss and significant decrease in working capital and cash, potentially impacting future dividends or share value. The material weakness in internal controls could also be a concern.
• Creditors (Fifth Third Bank, DFC): The company required a waiver for a debt covenant, indicating potential financial strain, though compliance was restored. The upcoming maturity of the Credit Agreement in April 2026 presents refinancing risk.
• Employees: New hires in finance and revenue cycle management indicate growth and restructuring in those areas.
• Customers (Hospitals/Patients): Continued investment in new equipment (Esprit, LINAC) and expansion of direct patient services facilities (Rhode Island, Mexico) suggests ongoing commitment to service delivery and expansion of treatment options.
• Suppliers (Elekta, Mevion, Solutech, Mobius Imaging): Ongoing significant related party transactions and service commitments indicate continued business relationships.

Next Steps

• Negotiate an extension to the Credit Agreement with Fifth Third Bank, which matures in April 2026.
• Finance commitments for two Leksell Gamma Knife Esprit Systems and two LINAC systems totaling $7,884,000.
• Continue implementing the remediation plan for the material weakness in internal controls, including assessing the need for additional finance and accounting resources.
• Newco in Guadalajara, Mexico, is expected to begin treating patients in Q2 2026.
• Monitor the impact of the One Big Beautiful Bill Act (OBBBA) on U.S. cash taxes in 2025.

Key Dates

Recommendation

The company shows mixed results. While direct patient services revenue is growing and Q3 net loss improved, the significant year-to-date net loss (when excluding the prior year's one-time gain), substantial decline in cash and working capital, and the need for a debt covenant waiver raise concerns about liquidity and financial stability. The upcoming maturity of a major credit facility adds uncertainty. However, the company is actively expanding its direct patient services segment, investing in new equipment, and addressing internal control issues. A "hold" recommendation is appropriate as the company navigates these challenges and executes its growth strategy, but investors should closely monitor liquidity, debt refinancing, and the effectiveness of internal control remediation.

Keywords

medical equipment leasing, radiation therapy, Gamma Knife, PBRT, proton beam therapy, cancer treatment, SEC filing, 10-Q, financial results, healthcare technology, debt covenants, liquidity, internal controls, ASHS